Clapham P R, Weber J N, Whitby D, McIntosh K, Dalgleish A G, Maddon P J, Deen K C, Sweet R W, Weiss R A
Chester Beatty Laboratories, Institute of Cancer Research, London, UK.
Nature. 1989 Jan 26;337(6205):368-70. doi: 10.1038/337368a0.
The CD4 antigen has been subverted as a receptor by the human and simian immunodeficiency viruses (HIV-1, HIV-2 and SIV). Several groups have reported that recombinant, soluble forms of the CD4 molecule (sCD4) block the infection of T lymphocytes by HIV-1, as CD4 binds the HIV envelope glycoprotein, gp120, with high affinity. We now report that sCD4 blocks diverse strains of HIV-1, HIV-2 and SIV, but is less effective for HIV-2. The blocking effect is apparent even after adsorption of virions to CD4 cells. Soluble CD4 prevents HIV infection of T-lymphocytic and myelomonocytic cell lines, but neither sCD4 nor anti-CD4 antibodies inhibit infection of glioma and rhabdomyosarcoma cell lines.
人类免疫缺陷病毒（HIV-1、HIV-2）和猿猴免疫缺陷病毒（SIV）已将CD4抗原作为受体加以利用。多个研究小组报告称，重组可溶性CD4分子（sCD4）可阻断HIV-1对T淋巴细胞的感染，因为CD4能与HIV包膜糖蛋白gp120高亲和力结合。我们现在报告，sCD4可阻断多种HIV-1、HIV-2和SIV毒株，但对HIV-2的效果较差。即使病毒粒子吸附到CD4细胞后，阻断效果依然明显。可溶性CD4可防止HIV感染T淋巴细胞系和骨髓单核细胞系，但sCD4和抗CD4抗体均不能抑制对胶质瘤和横纹肌肉瘤细胞系的感染。
